By doing so, we identified a VEGF-A protein overexpression signature as a statistically significant predictor of malignancy, discovered VEGF-A ligand DNA variants in GIST, and provided other possible targets in future design of anti-VEGF-directed therapy against GIST. This evidence concerns the gene VEGFA and gastrointestinal stromal tumor.